We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
EyePoint Pharmaceuticals Inc | NASDAQ:EYPT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.08 | 0.45% | 17.71 | 17.67 | 17.75 | 18.04 | 17.02 | 17.42 | 43,457 | 15:23:20 |
The Investor Day will feature commentary from EyePoint’s management team as well as key opinion leader guest speakers Carl D. Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University and Charles C. Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas. The agenda includes a discussion on the science behind EyePoint's Durasert® drug delivery platform, Phase 2 plans for EYP-1901, an investigational sustained delivery anti-VEGF treatment initially targeting wet AMD and a financial update.
A webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company website at www.eyepointpharma.com. The replay will be available for 90 days after the event.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Investors:
Christina TartagliaStern IRDirect: 212-698-8700christina.tartaglia@sternir.com
Media Contact
Amy PhillipsGreen Room CommunicationsDirect: 412-327-9499aphillips@greenroompr.com
1 Year EyePoint Pharmaceuticals Chart |
1 Month EyePoint Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions